Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Allergan plcAGN · Entity 149298 | Director | May 02, 2018 | May 04, 2018 |
| Amneal Pharmaceuticals, Inc.AMRX · Entity 820 | Director · Executive Chairman | May 07, 2019 | May 09, 2019 |
| Keenova Therapeutics plcNONE · Entity 28960 | Director | July 15, 2026 | July 18, 2026 |
| MYRIAD GENETICS INCMYGN · Entity 5953 | Director | June 04, 2026 | June 05, 2026 |
| TherapeuticsMD, Inc.TXMD · Entity 7541 | Director | September 29, 2022 | October 03, 2022 |
| ZIMMER BIOMET HOLDINGS, INC.ZBH · Entity 3278 | Director | March 31, 2017 | April 04, 2017 |
| Zoetis Inc.ZTS · Entity 679 | Director | May 13, 2026 | May 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Allergan plc
Report date May 02, 2018 · Filed May 04, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary Shares, par value $0.0001SEC Table I · non-derivative | Direct | 263,729 |
Reported balance
After 2018-05-02 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2018-05-02 · Grant · Acquired 1,985 · Balance 263,729 F1: These restricted stock units shall vest 100% on the earlier of (i) the day before the 2019 Annual General Meeting of Shareholders and (ii) May 2, 2019. F2: Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc. |
| Ordinary Shares, par value $0.0001SEC Table I · non-derivative | IndirectPaul Bisaro LLC | 120,000 |
Reported balance
Holding disclosure · report date 2018-05-02 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 120,000 |
Filing footnotes · ownership attribution and instrument terms
F1: These restricted stock units shall vest 100% on the earlier of (i) the day before the 2019 Annual General Meeting of Shareholders and (ii) May 2, 2019.
F2: Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc.
Amneal Pharmaceuticals, Inc.
Report date May 07, 2019 · Filed May 09, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 29,454 |
Ending reported balance
After 2019-05-07 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2019-05-07 · Exercise / conversion · Acquired 24,983 · Balance 41,983 F1: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Row 2 · 2019-05-07 · Tax withholding · Disposed 12,529 · Balance 29,454 F3: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 74,950 |
Reported balance
After 2019-05-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-05-07 · Exercise / conversion · Disposed 24,983 · Balance 74,950 F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F4: On May 7, 2018, the reporting person was granted 99,933 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. The restricted stock units do not expire. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3.
F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
F3: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units.
F4: On May 7, 2018, the reporting person was granted 99,933 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. The restricted stock units do not expire.
Keenova Therapeutics plc
Report date July 15, 2026 · Filed July 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 46,749 |
Reported balance
After 2026-07-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-15 · Grant · Acquired 4,406 · Balance 46,749 F1: Upon vesting, each restricted stock unit ("RSU") will be settled in ordinary shares of the Issuer at one share per RSU. F2: The RSUs will vest on the earlier of (i) the first anniversary of the grant date and (ii) the date of the Issuer's next annual general meeting of shareholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Upon vesting, each restricted stock unit ("RSU") will be settled in ordinary shares of the Issuer at one share per RSU.
F2: The RSUs will vest on the earlier of (i) the first anniversary of the grant date and (ii) the date of the Issuer's next annual general meeting of shareholders.
MYRIAD GENETICS INC
Report date June 04, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 157,142 |
Reported balance
After 2026-06-04 transaction · row 1
1 source rowRow 1 · 2026-06-04 · Grant · Acquired 59,701 · Balance 157,142 F1: Consists of restricted stock units granted pursuant to the Issuer's 2026 Employee, Director and Consultant Equity Incentive Plan, as amended. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and vests upon the earlier of (a) the first anniversary of the date of grant or (b) the date of the next annual meeting of stockholders following such grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of restricted stock units granted pursuant to the Issuer's 2026 Employee, Director and Consultant Equity Incentive Plan, as amended. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and vests upon the earlier of (a) the first anniversary of the date of grant or (b) the date of the next annual meeting of stockholders following such grant.
TherapeuticsMD, Inc.
Report date September 29, 2022 · Filed October 03, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 5,000 |
Reported balance
After 2022-09-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-09-29 · Grant · Acquired 5,000 · Balance 5,000 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the Issuer. The RSU's will vest on September 29, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the Issuer. The RSU's will vest on September 29, 2023.
ZIMMER BIOMET HOLDINGS, INC.
Report date March 31, 2017 · Filed April 04, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Phantom Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $121.49 | Direct | 3,095.293 |
Reported balance
After 2017-03-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-03-31 · Grant · Acquired 97.745 · Balance 3,095.293 F1: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. ("Company") Deferred Compensation Plan for Non-Employee Directors. F2: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3: Units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director. F4: Includes 5.918 phantom stock units accrued on January 27, 2017 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. ("Company") Deferred Compensation Plan for Non-Employee Directors.
F2: The Conversion or Exercise Price of Derivative Security is 1-for-1.
F3: Units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director.
F4: Includes 5.918 phantom stock units accrued on January 27, 2017 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
Zoetis Inc.
Report date May 13, 2026 · Filed May 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 27,862 |
Reported balance
After 2026-05-13 transaction · row 1
1 source rowRow 1 · 2026-05-13 · Purchase · Acquired 2,000 · Balance 27,862 F1: The Price reported in Table I, Column 4 is the price at which these shares were purchased in a single transaction. |
Filing footnotes · ownership attribution and instrument terms
F1: The Price reported in Table I, Column 4 is the price at which these shares were purchased in a single transaction.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Impax Laboratories, LLC
Report date May 04, 2018 · Filed May 08, 2018
Section 16 reporting ended · disclosed 2018-05-08. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.70 · Expires 2027-03-27 | Direct | 0 |
Reported balance
After 2018-05-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-05-04 · Disposition to issuer · Disposed 850,000 · Balance 0 F1: Options disposed of pursuant to the terms of the Business Combination Agreement, dated as of October 17, 2017, by and among Impax Laboratories, Inc., Atlas Holdings, Inc. ("Holdco"), K2 Merger Sub Corporation and Amneal Pharmaceuticals LLC, as amended by Amendment No. 1, dated as of November 21, 2017, and Amendment No. 2, dated as of December 16, 2017 (the "BCA"), according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock of Holdco equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA at a per-share exercise price equal to the per-share exercise price of such Option. |
Filing footnotes · ownership attribution and instrument terms
F1: Options disposed of pursuant to the terms of the Business Combination Agreement, dated as of October 17, 2017, by and among Impax Laboratories, Inc., Atlas Holdings, Inc. ("Holdco"), K2 Merger Sub Corporation and Amneal Pharmaceuticals LLC, as amended by Amendment No. 1, dated as of November 21, 2017, and Amendment No. 2, dated as of December 16, 2017 (the "BCA"), according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock of Holdco equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA at a per-share exercise price equal to the per-share exercise price of such Option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 01, 2017 Filed Feb 4, 2017 01:32 UTC | Allergan plc AGN · Entity 149298 | GrantOrdinary Shares, par value $0.0001 | 7,105 | $229.32 | $1,629,318.60 |
DisclosureSEC source: 0001179110-17-001736 · edgar.xml · nonDerivative · entry 1 BISARO PAUL · CIK 0001237253 · Director · Exec Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,867 Read SEC document |
| February 01, 2017 Filed Feb 7, 2017 01:08 UTC Amendment | Allergan plc AGN · Entity 149298 | ConversionOrdinary Shares, par value $0.0001 · Derivative | 7,105 | $0.00 Strike: $229.32 | $0.00 |
DisclosureSEC source: 0001179110-17-001833 · edgar.xml · derivative · entry 4 BISARO PAUL · CIK 0001237253 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 7,105 shares Expires 2017-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Represents performance-based restricted share units ("PSUs") which vested on February 1, 2017, following certification of achievement by issuer of certain performance criteria. Each PSU represented a contingent right to receive ordinary shares of the Issuer equal to the product of the applicable performance multiple and the target number of shares underlying the PSU, as set forth in the award agreement between the Issuer and Reporting Person. F2 · derivative.expiration_date: Represents performance-based restricted share units ("PSUs") which vested on February 1, 2017, following certification of achievement by issuer of certain performance criteria. Each PSU represented a contingent right to receive ordinary shares of the Issuer equal to the product of the applicable performance multiple and the target number of shares underlying the PSU, as set forth in the award agreement between the Issuer and Reporting Person. Read SEC document |
| February 01, 2017 Filed Feb 7, 2017 01:08 UTC Amendment | Allergan plc AGN · Entity 149298 | Tax withholdingOrdinary Shares, par value $0.0001 | 3,411 | $229.32 | $782,210.52 |
DisclosureSEC source: 0001179110-17-001833 · edgar.xml · nonDerivative · entry 2 BISARO PAUL · CIK 0001237253 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 305,456 F1 · balance_after: Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc. F3 · balance_after: This amendment to the Form 4 filed on February 3, 2017 is being filed in order to: (1) correct an administrative error whereby 120,000 ordinary shares, par value $0.0001 (the "Ordinary Shares"), were inadvertently excluded in the Reporting Person's direct ownership value and (2) properly reflect 120,000 shares held in Paul Bisaro LLC ("LLC"), an LLC in which Mr. Bisaro retains an ownership interest and might be deemed to have or share investment control. Read SEC document |
| February 01, 2017 Filed Feb 7, 2017 01:08 UTC Amendment | Allergan plc AGN · Entity 149298 | GrantOrdinary Shares, par value $0.0001 | 7,105 | $229.32 | $1,629,318.60 |
DisclosureSEC source: 0001179110-17-001833 · edgar.xml · nonDerivative · entry 1 BISARO PAUL · CIK 0001237253 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 308,867 Read SEC document |
| December 31, 2016 Filed Jan 4, 2017 20:44 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantPhantom Stock Units · Derivative | 114.856 | $0.00 Strike: $103.39 | $0.00 |
DisclosureSEC source: 0000911916-17-000006 · edgar.xml · derivative · entry 1 BISARO PAUL · CIK 0001237253 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,991.63 Underlying: Common Stock · 114.856 shares Expires not disclosed F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. ("Company") Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: Units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director. F3 · derivative.expiration_date: Units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director. F4 · balance_after: Includes 5.461 phantom stock units accrued on October 28, 2016 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| September 30, 2016 Filed Oct 4, 2016 20:20 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantPhantom Stock Units · Derivative | 91.791 | $0.00 Strike: $129.37 | $0.00 |
DisclosureSEC source: 0000911916-16-000664 · edgar.xml · derivative · entry 1 BISARO PAUL · CIK 0001237253 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,871.313 Underlying: Common Stock · 91.791 shares Expires not disclosed F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. ("Company") Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: Units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director. F3 · derivative.expiration_date: Units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director. F4 · balance_after: Includes 4.962 phantom stock units accrued on July 29, 2016 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.